This research study is determining if a drug called Pimavanserin if safe and effective in the
treatment of the symptoms of Tourette Syndrome. Pimavanserin is an investigational drug for
Tourette Syndrome, which means it has not been approved by the United States Food and Drug
Administration (FDA) to treat Tourette Syndrome. Pimavanserin has been approved by the FDA as
a treatment for hallucinations in Parkinson's Disease. It is currently marketed under the
name NUPLAZID (pimavanserin) capsules by Acadia Pharmaceuticals.